This site is intended for healthcare professionals
scientific kidney
Complement-mediated kidney diseases (CMKDs) Learning Zone
Declaration of sponsorship Novartis Pharma AG

Congress highlights

Declaration of sponsorship Novartis Pharma AG
Read time: 30 mins
Last updated:22nd Dec 2022
Published:22nd Dec 2022

ASN 2022 congress highlights

Join Dr Carla Nester as she discusses numerous findings presented at the American Society of Nephrology (ASN) 2022 Congress, which was held in November in Orlando. Dr Nester provides a comprehensive overview of the presentations, which included data on new treatment targets, the latest findings on nephritic factors and novel treatments for C3 glomerulopathy (C3G) and other complement-mediated kidney diseases (CMKDs).

Complement is known to play a role in several kidney diseases. Here, Dr Carla Nester, Director of Paediatric Nephrology, Dialysis and Transplantation at the Stead Family Children’s Hospital, University of Iowa, describes the emergence of complement inhibitors as a potential therapeutic approach for such diseases. She also discusses research into related conditions presented at the ASN 2022 Congress.